Study on Cisplatin-based Chemotherapy and Atezolizumab for Certain Stages of Resected Non-small Cell Lung Cancer (NSCLC) and Monitoring Circulating Tumor DNA

Inclusion Criteria

• Must provide written consent and agree to share personal health information.
• Be 18 years or older.
• Have a good performance status score of 0 or 1.
• Have had complete surgical removal of stage I (tumors 4cm or larger), IIA, IIB, or select stage III NSCLC with no cancer left behind.
• Have either squamous or non-squamous NSCLC.
• Surgery must have been completed within 60 days before starting treatment.
• Must have tissue samples available for testing.
• Must have adequate organ function based on lab tests.
• Women of childbearing potential must have a negative pregnancy test and agree to use effective birth control during treatment and for 5 months after.
• Men must agree to use condoms or remain abstinent during treatment and for 5 months after.
• Must be able to understand and follow study procedures.

Exclusion Criteria

• Tumors with small cell or large cell neuroendocrine features are not eligible.
• Tumors with specific genetic mutations (EGFR or ALK) are not eligible.
• No prior chemotherapy, radiation, or immunotherapy for this lung cancer.
• No other active cancers.
• No history of certain diseases like leptomeningeal disease.
• No prior treatment with certain immune therapies.
• No recent live vaccines.
• Not currently in another investigational study.
• No immune deficiencies or chronic steroid use.
• No severe allergies to atezolizumab.
• No active autoimmune diseases.
• No significant lung disease or pneumonitis.
• No uncontrolled fluid buildup in the body.
• No uncontrolled high calcium levels.
• No recent significant heart disease.
• No severe infections recently.
• No history of HIV, active hepatitis B or C, or tuberculosis.
• No prior organ transplants.
• No conditions that could interfere with the study.
• Not pregnant or breastfeeding.